Our history.

• First participant dosed with TT-P34 in Phase 1 clinical trial in healthy volunteers and participants with Parkinson’s Disease
• Received regulatory approval from the Dutch METC to initiate the first-in-human clinical trial, P34-101
• Published SorCS-receptor discovery in iScience
• Received Eurostars grant for the Hearing Loss project, RE-HEAR, together with CILcare and FHNW

‍

• Teitur moved into new facilities at Incuba Skejby
• Receives grant from Innobooster to support TT-P34 biomarker development

• Raised € 28M Series A round to advance development of SorCS2-peptides into clinical development. Financing was co-led by Sunstone Life Science Ventures and Sound Bioventures with participation from Industrifonden, Innovestor’s Life Science Fund and P53 Invest

• Patent filed covering 3rd generation of cyclic and lipidated SorCS-receptor peptide mimetics for therapeutic use in neurodegeneration
• Received Innobooster grant to develop SorCS2-candidate towards IND

• Secured € 400.000 Seed round fromSunstone Life Science Ventures to demonstrate in vivo proof of concept for SorCS2-derived peptides

• Co-founders Simon Mølgaard, Anders Dalby, Mathias Kaas and Simon Glerup launch Teitur Trophics with announcement of a €1.3M investment from BioInnovation Institute as part of the BII Creation House program
• Patent filed covering 2nd generation of cyclic SorCS-receptor peptide mimetics for therapeutic use in neurodegeneration

• Patent filed covering 1st generation of SorCS-receptor peptide mimetics for therapeutic use in neurodegeneration